Fineline Cube

Follow:
14409 Articles
Merck's Recarbrio Approved by NMPA for Hospital-Acquired Infections and Complicated UTIs
CompanyDrug

Merck’s Recarbrio Approved by NMPA for Hospital-Acquired Infections and Complicated UTIs

Abbisko Therapeutics Gets FDA Green Light for Phase I Study of ABSK131 Inhibitor
CompanyDrug

Abbisko Therapeutics Gets FDA Green Light for Phase I Study of ABSK131 Inhibitor

Hefan Medicine's Piracetam Production and Marketing Suspended Over GMP Violations
CompanyDrug

Hefan Medicine’s Piracetam Production and Marketing Suspended Over GMP Violations

InventisBio's Oral TYK2 Inhibitor D-2570 Achieves Positive Results in Phase II Psoriasis Study
CompanyDrug

InventisBio’s Oral TYK2 Inhibitor D-2570 Achieves Positive Results in Phase II Psoriasis Study

Shanghai Henlius Biotech's Serplulimab Approved for First-Line nsNSCLC Treatment in China
CompanyDrug

Shanghai Henlius Biotech’s Serplulimab Approved for First-Line nsNSCLC Treatment in China

Zhejiang Huahai Pharmaceutical Initiates Clinical Study for HB0056 in New Zealand
CompanyDrug

Zhejiang Huahai Pharmaceutical Initiates Clinical Study for HB0056 in New Zealand

HutchMed and Innovent Biologics' Fruzaqla-Tyvyt Combo Gets NMPA Conditional Approval for Endometrial Cancer
CompanyDrug

HutchMed and Innovent Biologics’ Fruzaqla-Tyvyt Combo Gets NMPA Conditional Approval for Endometrial Cancer

Acotec Scientific's AcoArt Camellia Receives NMPA Approval for Coronary Artery Disease Treatment
CompanyMedical Device

Acotec Scientific’s AcoArt Camellia Receives NMPA Approval for Coronary Artery Disease Treatment

CompanyDeals

REGiMMUNE and San Fu Biotech Ink Deal for RGI-2001 Development in Asia

AccurEdit Therapeutics' ART001 Shows Over 90% TTR Reduction in ATTR Amyloidosis Trial
CompanyDrug

AccurEdit Therapeutics’ ART001 Shows Over 90% TTR Reduction in ATTR Amyloidosis Trial

Sanofi Announces EUR 1 Billion Investment for New Beijing Manufacturing Plant
Company

Sanofi Announces EUR 1 Billion Investment for New Beijing Manufacturing Plant

Huadong Medicine's SaiYueXin Biosimilar Accepted for Review by NMPA for Pediatric Psoriasis
CompanyDrug

Huadong Medicine’s SaiYueXin Biosimilar Accepted for Review by NMPA for Pediatric Psoriasis